NCT03851627View on ClinicalTrials.gov

Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism

PHASE4RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 25, 2022

Primary Completion Date

September 30, 2028

Study Completion Date

December 31, 2028

Conditions
Fatty LiverOverweight/ObesityPrediabetes/Type2 Diabetes MellitusHypogonadism, Male
Interventions
DRUG

Testosterone Undecanoate

1000mg/4ml i.m. initial, after 6 weeks, every 10 weeks thereafter

DRUG

Placebo

Placebo Arm

Trial Locations (1)

1090

RECRUITING

Abt. für Endokrinologie & Stoffwechsel, Univ. Klin f. Innere Medizin III, Vienna

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Alexandra Kautzky-Willer

OTHER